NCT07092514View on ClinicalTrials.gov

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

April 17, 2029

Study Completion Date

October 31, 2034

Conditions
Thyroid CancerCancer of the Thyroid
Interventions
DRUG

Lenvatinib

Lenvatinib is an oral drug which will be administered on an outpatient basis at a dose of 24 mg daily or 10 mg daily for an unlimited number of cycles.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER